8H6T
| Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor | Descriptor: | (1R,3S)-3-{3-[(pyridin-2-yl)amino]-1H-pyrazol-5-yl}cyclopentyl propan-2-ylcarbamate, Cyclin-dependent kinase 2, G1/S-specific cyclin-E1 | Authors: | Ren, X. | Deposit date: | 2022-10-18 | Release date: | 2023-02-22 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design. Acs Med.Chem.Lett., 14, 2023
|
|
8H6P
| Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor | Descriptor: | (7S,10R)-11-oxa-2,4,5,13,17,23-hexaazatetracyclo[17.3.1.1~3,6~.1~7,10~]pentacosa-1(23),3(25),5,19,21-pentaene-12,18-dione, Cyclin-dependent kinase 2, G1/S-specific cyclin-E1 | Authors: | Ren, X. | Deposit date: | 2022-10-18 | Release date: | 2023-02-22 | Last modified: | 2023-03-29 | Method: | X-RAY DIFFRACTION (2.44 Å) | Cite: | Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design. Acs Med.Chem.Lett., 14, 2023
|
|
2LWF
| Structure of N-terminal domain of a plant Grx | Descriptor: | Monothiol glutaredoxin-S16, chloroplastic | Authors: | Feng, Y. | Deposit date: | 2012-07-28 | Release date: | 2013-05-22 | Last modified: | 2024-05-15 | Method: | SOLUTION NMR | Cite: | Structural insights into the N-terminal GIY-YIG endonuclease activity of Arabidopsis glutaredoxin AtGRXS16 in chloroplasts. Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
7X1N
| Crystal structure of MEF2D-MRE complex | Descriptor: | DNA (5'-D(P*AP*AP*CP*TP*AP*TP*TP*TP*AP*TP*AP*AP*G)-3'), DNA (5'-D(P*TP*CP*TP*TP*AP*TP*AP*AP*AP*TP*AP*GP*T)-3'), Myocyte enhancer factor 2D/deleted in azoospermia associated protein 1 fusion protein | Authors: | Zhang, H, Zhang, M, Wang, Q.Q, Chen, Z, Chen, S.J, Meng, G. | Deposit date: | 2022-02-24 | Release date: | 2022-05-25 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (3.315 Å) | Cite: | Functional, structural, and molecular characterizations of the leukemogenic driver MEF2D-HNRNPUL1 fusion. Blood, 140, 2022
|
|
7V68
| An Agonist and PAM-bound Class A GPCR with Gi protein complex structure | Descriptor: | 3-amino-5-chloro-N-cyclopropyl-4-methyl-6-[2-(4-methylpiperazin-1-yl)-2-oxoethoxy]thieno[2,3-b]pyridine-2-carboxamide, 4-(4,5-dihydro-1,2-oxazol-3-yloxy)-N,N,N-trimethylbut-2-yn-1-aminium, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, ... | Authors: | Wang, J.J, Wu, L.J, Wu, M, Hua, T, Liu, Z.J, Wang, T. | Deposit date: | 2021-08-20 | Release date: | 2022-05-11 | Last modified: | 2022-11-23 | Method: | ELECTRON MICROSCOPY (3.4 Å) | Cite: | The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands. Nat Commun, 13, 2022
|
|
7V6A
| Cry-EM structure of M4-c110-G protein complex | Descriptor: | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(i) subunit alpha-1, ... | Authors: | Wang, J.J, Wu, M, Wu, L.J, Hua, T, Liu, Z.J, Wang, T. | Deposit date: | 2021-08-20 | Release date: | 2022-05-11 | Last modified: | 2022-11-23 | Method: | ELECTRON MICROSCOPY (3.6 Å) | Cite: | The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands. Nat Commun, 13, 2022
|
|
7V69
| Cryo-EM structure of a class A GPCR-G protein complex | Descriptor: | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(i) subunit alpha-1, ... | Authors: | Wang, J.J, Wu, M, Wu, L.J, Hua, T, Liu, Z.J, Wang, T. | Deposit date: | 2021-08-20 | Release date: | 2022-05-11 | Last modified: | 2022-11-23 | Method: | ELECTRON MICROSCOPY (3.4 Å) | Cite: | The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands. Nat Commun, 13, 2022
|
|
8XV9
| Fedratinib-bound human SLC19A3 | Descriptor: | N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide, Soluble cytochrome b562,Thiamine transporter 2 | Authors: | Dang, Y, Wang, G.P, Zhang, Z. | Deposit date: | 2024-01-14 | Release date: | 2024-03-27 | Last modified: | 2024-06-12 | Method: | ELECTRON MICROSCOPY (3.8 Å) | Cite: | Substrate and drug recognition mechanisms of SLC19A3. Cell Res., 34, 2024
|
|
8XV2
| Thiamine-bound human SLC19A3 | Descriptor: | 3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM, Soluble cytochrome b562,Thiamine transporter 2 | Authors: | Dang, Y, Wang, G.P, Zhang, Z. | Deposit date: | 2024-01-14 | Release date: | 2024-03-27 | Last modified: | 2024-06-12 | Method: | ELECTRON MICROSCOPY (3.7 Å) | Cite: | Substrate and drug recognition mechanisms of SLC19A3. Cell Res., 34, 2024
|
|
8XV5
| Pyridoxamine-bound human SLC19A3 | Descriptor: | 4-(AMINOMETHYL)-5-(HYDROXYMETHYL)-2-METHYLPYRIDIN-3-OL, Soluble cytochrome b562,Thiamine transporter 2 | Authors: | Dang, Y, Wang, G.P, Zhang, Z. | Deposit date: | 2024-01-14 | Release date: | 2024-03-27 | Last modified: | 2024-06-12 | Method: | ELECTRON MICROSCOPY (3.7 Å) | Cite: | Substrate and drug recognition mechanisms of SLC19A3. Cell Res., 34, 2024
|
|
8ZMR
| Vesamicol-bound VAChT | Descriptor: | Maltose/maltodextrin-binding periplasmic protein,Vesicular acetylcholine transporter,DARPinoff7, vesamicol | Authors: | Zhang, Z, Zhang, Y, Dai, F, Zhang, Y.X, Lee, C.-H. | Deposit date: | 2024-05-23 | Release date: | 2024-06-19 | Last modified: | 2024-09-18 | Method: | ELECTRON MICROSCOPY (3.5 Å) | Cite: | Structural insights into VAChT neurotransmitter recognition and inhibition. Cell Res., 34, 2024
|
|
8ZMS
| Acetylcholine-bound VAChT | Descriptor: | ACETYLCHOLINE, Maltose/maltodextrin-binding periplasmic protein,Vesicular acetylcholine transporter,DARPinoff7 | Authors: | Zhang, Z, Zhang, Y, Dai, F, Zhang, Y.X, Lee, C.-H. | Deposit date: | 2024-05-23 | Release date: | 2024-06-19 | Last modified: | 2024-09-18 | Method: | ELECTRON MICROSCOPY (3.7 Å) | Cite: | Structural insights into VAChT neurotransmitter recognition and inhibition. Cell Res., 34, 2024
|
|
6WNY
| Crystal structure of BACE1 in complex with (Z)-fluoro-olefin containing compound 15 | Descriptor: | 6-[(Z)-2-{3-[(1S,5S,6S)-3-amino-5-methyl-1-(morpholine-4-carbonyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl]-4-fluorophenyl}-1-fluoroethenyl]pyridine-3-carbonitrile, Beta-secretase 1, IODIDE ION | Authors: | Whittington, D.A. | Deposit date: | 2020-04-23 | Release date: | 2020-06-03 | Last modified: | 2024-04-03 | Method: | X-RAY DIFFRACTION (1.86 Å) | Cite: | The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement. Bioorg.Med.Chem.Lett., 30, 2020
|
|
2QKM
| |
8TQD
| NF-Kappa-B1 Bound with a Covalent Inhibitor | Descriptor: | 1-(2-bromo-4-chlorophenyl)-N-{(3S)-1-[(E)-iminomethyl]pyrrolidin-3-yl}methanesulfonamide, Nuclear factor NF-kappa-B p105 subunit | Authors: | Hilbert, B.J. | Deposit date: | 2023-08-07 | Release date: | 2024-04-24 | Last modified: | 2024-05-22 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Cell, 187, 2024
|
|
4TPP
| 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors | Descriptor: | 1-[4-(3-{[1-(quinolin-2-yl)azetidin-3-yl]oxy}quinoxalin-2-yl)piperidin-1-yl]ethanone, GLYCEROL, SULFATE ION, ... | Authors: | Chmait, S. | Deposit date: | 2014-06-09 | Release date: | 2014-12-17 | Last modified: | 2024-10-23 | Method: | X-RAY DIFFRACTION (2.65 Å) | Cite: | Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility. Bioorg.Med.Chem., 22, 2014
|
|
4MVH
| Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor | Descriptor: | 1H-benzimidazol-2-yl(4-{[3-(morpholin-4-yl)pyrazin-2-yl]oxy}phenyl)methanone, SULFATE ION, ZINC ION, ... | Authors: | Chmait, S, Jordan, S. | Deposit date: | 2013-09-24 | Release date: | 2013-10-23 | Last modified: | 2014-01-15 | Method: | X-RAY DIFFRACTION (2.496 Å) | Cite: | Design, Optimization, and Biological Evaluation of Novel Keto-Benzimidazoles as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A). J.Med.Chem., 56, 2013
|
|
4PHW
| |
4MUW
| Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor | Descriptor: | 2-{4-[(6,7-difluoro-1H-benzimidazol-2-yl)amino]phenoxy}-N-methyl-3,4'-bipyridin-2'-amine, GLYCEROL, SULFATE ION, ... | Authors: | Chmait, S, Jordan, S. | Deposit date: | 2013-09-23 | Release date: | 2013-10-23 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2.639 Å) | Cite: | Design, Optimization, and Biological Evaluation of Novel Keto-Benzimidazoles as Potent and Selective Inhibitors of Phosphodiesterase 10A (PDE10A). J.Med.Chem., 56, 2013
|
|
4TPM
| |
1D4V
| Crystal structure of trail-DR5 complex | Descriptor: | DEATH RECEPTOR 5, TNF-RELATED APOPTOSIS INDUCING LIGAND | Authors: | Mongkolsapaya, J, Grimes, J.M, Stuart, D.I, Jones, E.Y, Screaton, G.R. | Deposit date: | 1999-10-06 | Release date: | 1999-11-01 | Last modified: | 2024-10-30 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation Nat.Struct.Biol., 6, 1999
|
|
8G1Q
| Co-crystal structure of Compound 1 in complex with the bromodomain of human SMARCA4 and pVHL:ElonginC:ElonginB | Descriptor: | DI(HYDROXYETHYL)ETHER, Elongin-B, Elongin-C, ... | Authors: | Ghimire Rijal, S, Wurz, R.P, Vaish, A. | Deposit date: | 2023-02-02 | Release date: | 2023-07-26 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (3.73 Å) | Cite: | Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun, 14, 2023
|
|
8G1P
| Co-crystal structure of Compound 11 in complex with the bromodomain of human SMARCA2 and pVHL:ElonginC:ElonginB | Descriptor: | (2~{S},4~{R})-~{N}-[[2-[2-[4-[[4-[3-azanyl-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]methyl]phenyl]ethoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide, Elongin-B, Elongin-C, ... | Authors: | Ghimire Rijal, S, Wurz, R.P, Vaish, A. | Deposit date: | 2023-02-02 | Release date: | 2023-07-26 | Last modified: | 2023-08-30 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. Nat Commun, 14, 2023
|
|
3CPB
| Crystal structure of the VEGFR2 kinase domain in complex with a bisamide inhibitor | Descriptor: | N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide, Vascular endothelial growth factor receptor 2 | Authors: | Whittington, D.A, Long, A.M, Rose, P, Gu, Y, Zhao, H. | Deposit date: | 2008-03-31 | Release date: | 2008-06-17 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective, and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit. J.Med.Chem., 51, 2008
|
|
3CPC
| Crystal structure of the VEGFR2 kinase domain in complex with a pyridone inhibitor | Descriptor: | 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one, Vascular endothelial growth factor receptor 2 | Authors: | Whittington, D.A, Long, A.M, Rose, P, Gu, Y, Zhao, H. | Deposit date: | 2008-03-31 | Release date: | 2008-06-17 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (2.4 Å) | Cite: | Discovery of Aryl Aminoquinazoline Pyridones as Potent, Selective, and Orally Efficacious Inhibitors of Receptor Tyrosine Kinase c-Kit. J.Med.Chem., 51, 2008
|
|